Bioqube Ventures

Bioqube Ventures is a specialist life sciences investment firm focusing on early-stage biotechnology companies in Europe. The firm invests in companies developing first- or best-in-class therapeutics to address major unmet medical needs. Bioqube Ventures is stage agnostic, building balanced portfolios that support companies from inception through early clinical milestones. The firm has offices in Belgium and the United States, reflecting its global reach.

Founded in 2015, Bioqube Ventures has backed and supported over 20 biotech companies, beginning with an incubation model on the Janssen Pharmaceutica R&D campus in Belgium. Early successes validated their hands-on investment approach and led to multiple high-value exits. In 2020, Bioqube Ventures launched the Bioqube Factory Fund I, a €110 million fund with a clear focus on the discovery and development of new therapeutic platforms and assets. This diversified investment strategy includes a venture creation model and industry guidance through selected strategic partnerships.

Bioqube Ventures has established partnerships with organizations such as Johnson & Johnson Innovation – JJDC, Genmab, and IQVIA. These collaborations combine scientific insight with financial strength to help biotech innovators turn breakthrough science into lasting impact. The firm's portfolio includes companies like CatalYm, Spica Therapeutics, SynOx Therapeutics, Actithera, Egle Therapeutics, and Commit Biologics, among others. Bioqube Ventures is committed to delivering impactful medicines by investing in the most promising innovative science in Europe and the United States.